Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
220 hedge funds and large institutions have $658M invested in Sorrento Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 69 increasing their positions, 51 reducing their positions, and 18 closing their positions.
96% more call options, than puts
Call options by funds: $75.2M | Put options by funds: $38.4M
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
35% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 51
4% more funds holding
Funds holding: 212 → 220 (+8)
12% less capital invested
Capital invested by funds: $752M → $658M (-$93.7M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.4M |
| 2 |
BlackRock
New York
|
+$14.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7M |
| 4 |
D.E. Shaw & Co
New York
|
+$9.69M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$6.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.77M |
| 2 |
Capital Fund Management (CFM)
Paris,
France
|
-$3.19M |
| 3 |
Citigroup
New York
|
-$1.85M |
| 4 |
Millennium Management
New York
|
-$1.66M |
| 5 |
HW
Hancock Whitney
Gulfport,
Mississippi
|
-$1.21M |
SRNE Hedge Fund Activity: Q3 2021 in Review
220 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2021, worth a combined $658M — down 12% from $752M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SRNE positions and 18 closed out — a net gain of 12 holders — while 69 added to existing stakes and 51 trimmed.
The largest buyer was State Street, adding an estimated $17.4M. The largest seller was Susquehanna International Group, cutting an estimated $4.77M.
- 220 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2021, up from 212 in Q2 2021.
- Funds reported $658M of Sorrento Therapeutics, Inc. stock for Q3 2021, down 12% quarter-over-quarter.
- 30 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2021 and 18 closed out, a net change of +12 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2021 was State Street, an estimated $17.4M added.
- The largest Sorrento Therapeutics, Inc. seller in Q3 2021 was Susquehanna International Group, an estimated $4.77M sold.
Based on aggregated 13F filings for Q3 2021.